BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 16366598)

  • 1. (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells.
    Ho CY; Ludovici DW; Maharoof US; Mei J; Sechler JL; Tuman RW; Strobel ED; Andraka L; Yen HK; Leo G; Li J; Almond H; Lu H; DeVine A; Tominovich RM; Baker J; Emanuel S; Gruninger RH; Middleton SA; Johnson DL; Galemmo RA
    J Med Chem; 2005 Dec; 48(26):8163-73. PubMed ID: 16366598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
    Roberts WG; Whalen PM; Soderstrom E; Moraski G; Lyssikatos JP; Wang HF; Cooper B; Baker DA; Savage D; Dalvie D; Atherton JA; Ralston S; Szewc R; Kath JC; Lin J; Soderstrom C; Tkalcevic G; Cohen BD; Pollack V; Barth W; Hungerford W; Ung E
    Cancer Res; 2005 Feb; 65(3):957-66. PubMed ID: 15705896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel.
    Dinges J; Albert DH; Arnold LD; Ashworth KL; Akritopoulou-Zanze I; Bousquet PF; Bouska JJ; Cunha GA; Davidsen SK; Diaz GJ; Djuric SW; Gasiecki AF; Gintant GA; Gracias VJ; Harris CM; Houseman KA; Hutchins CW; Johnson EF; Li H; Marcotte PA; Martin RL; Michaelides MR; Nyein M; Sowin TJ; Su Z; Tapang PH; Xia Z; Zhang HQ
    J Med Chem; 2007 May; 50(9):2011-29. PubMed ID: 17425296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
    Glaser KB; Li J; Marcotte PA; Magoc TJ; Guo J; Reuter DR; Tapang P; Wei RQ; Pease LJ; Bui MH; Chen Z; Frey RR; Johnson EF; Osterling DJ; Olson AM; Bouska JJ; Luo Y; Curtin ML; Donawho CK; Michaelides MR; Tse C; Davidsen SK; Albert DH
    J Pharmacol Exp Ther; 2012 Dec; 343(3):617-27. PubMed ID: 22935731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
    Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
    Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice.
    Bäckman U; Christofferson R
    Pediatr Res; 2005 May; 57(5 Pt 1):690-5. PubMed ID: 15718357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-glucuronidation of the platelet-derived growth factor receptor tyrosine kinase inhibitor 6,7-(dimethoxy-2,4-dihydroindeno[1,2-C]pyrazol-3-yl)-(3-fluoro-phenyl)-amine by human UDP-glucuronosyltransferases.
    Yan Z; Caldwell GW; Gauthier D; Leo GC; Mei J; Ho CY; Jones WJ; Masucci JA; Tuman RW; Galemmo RA; Johnson DL
    Drug Metab Dispos; 2006 May; 34(5):748-55. PubMed ID: 16455802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
    Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma.
    Kim R; Emi M; Arihiro K; Tanabe K; Uchida Y; Toge T
    Cancer; 2005 May; 103(9):1800-9. PubMed ID: 15786421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of platelet-derived growth factor (PDGF) receptor autophosphorylation and PDGF-mediated cellular events by a quinoline derivative.
    Yagi M; Kato S; Kobayashi Y; Kubo K; Oyama S; Shimizu T; Nishitoba T; Isoe T; Nakamura K; Ohashi H; Kobayashi N; Iinuma N; Osawa T; Onose R; Osada H
    Exp Cell Res; 1997 Aug; 234(2):285-92. PubMed ID: 9260896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice.
    Blaskovich MA; Lin Q; Delarue FL; Sun J; Park HS; Coppola D; Hamilton AD; Sebti SM
    Nat Biotechnol; 2000 Oct; 18(10):1065-70. PubMed ID: 11017044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
    Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
    J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
    Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
    Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet-derived growth factor-BB, insulin-like growth factor-I, and phorbol ester activate different signaling pathways for stimulation of vascular smooth muscle cell migration.
    Pukac L; Huangpu J; Karnovsky MJ
    Exp Cell Res; 1998 Aug; 242(2):548-60. PubMed ID: 9683541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory mechanism of tranilast in human coronary artery smooth muscle cells proliferation, due to blockade of PDGF-BB-receptors.
    Watanabe S; Matsuda A; Suzuki Y; Kondo K; Ikeda Y; Hashimoto H; Umemura K
    Br J Pharmacol; 2000 May; 130(2):307-14. PubMed ID: 10807667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation.
    Kovalenko M; Gazit A; Böhmer A; Rorsman C; Rönnstrand L; Heldin CH; Waltenberger J; Böhmer FD; Levitzki A
    Cancer Res; 1994 Dec; 54(23):6106-14. PubMed ID: 7954456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.
    Boschelli DH; Wu Z; Klutchko SR; Showalter HD; Hamby JM; Lu GH; Major TC; Dahring TK; Batley B; Panek RL; Keiser J; Hartl BG; Kraker AJ; Klohs WD; Roberts BJ; Patmore S; Elliott WL; Steinkampf R; Bradford LA; Hallak H; Doherty AM
    J Med Chem; 1998 Oct; 41(22):4365-77. PubMed ID: 9784112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
    Mendel DB; Laird AD; Xin X; Louie SG; Christensen JG; Li G; Schreck RE; Abrams TJ; Ngai TJ; Lee LB; Murray LJ; Carver J; Chan E; Moss KG; Haznedar JO; Sukbuntherng J; Blake RA; Sun L; Tang C; Miller T; Shirazian S; McMahon G; Cherrington JM
    Clin Cancer Res; 2003 Jan; 9(1):327-37. PubMed ID: 12538485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphatidylinositol 3-kinase activity is required for the activation process of focal adhesion kinase by platelet-derived growth factor.
    Saito Y; Mori S; Yokote K; Kanzaki T; Saito Y; Morisaki N
    Biochem Biophys Res Commun; 1996 Jul; 224(1):23-6. PubMed ID: 8694818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,4-Dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors.
    Dinges J; Ashworth KL; Akritopoulou-Zanze I; Arnold LD; Baumeister SA; Bousquet PF; Cunha GA; Davidsen SK; Djuric SW; Gracias VJ; Michaelides MR; Rafferty P; Sowin TJ; Stewart KD; Xia Z; Zhang HQ
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4266-71. PubMed ID: 16759855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.